Impact of laparoscopic sleeve gastrectomy surgery on vasoactive mediators in morbid obese patients.
Phase 2
- Conditions
- Health Condition 1: E669- Obesity, unspecified
- Registration Number
- CTRI/2024/02/063079
- Lead Sponsor
- ADY HARDINGE MEDICAL COLLEGE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Morbidly Obese individuals with BMI more than 37.5;
Morbidly Obese individuals with BMI more than 32.5 with comorbidities like hypertension, diabetes mellitus, hypercholesterolemia, non alcoholic fatty liver disease, cardiovascular disease.
Exclusion Criteria
History of cerebrovascular accident in last 6 months.
Known case of Severe hepatic, cardiac, psychiatric diseases
Known case of Renal artery stenosis and renal disorders.
Patients lost to follow up.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in serum levels of angiotensinogen, renin, aldosterone, and free fatty acids 3 months after laparoscopic sleeve gastrectomy.Timepoint: Before and 3 months after surgery.
- Secondary Outcome Measures
Name Time Method 1.To calculate the percentage excess weight loss 3 months after laparoscopic sleeve gastrectomy. <br/ ><br>2.To correlate the percentage excess weight loss with the change in serum levels of angiotensinogen, renin, aldosterone and free fatty acids 3 months after laparoscopic sleeve gastrectomy.Timepoint: Before and 3 months after surgery.